A Phase 1a/1b Trial in Relapsed/Refractory Small Cell Lung Cancer to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

开始日期2025-12-11

申办/合作机构

SciTech Development LLC

NCT07149220

/ Recruiting临床1期IIT

Safety and Chemopreventive Efficacy of Fenretinide Mucoadhesive System in Subjects With Premalignant Oral Intraepithelial Neoplasia (OIN) Lesions: In Conjunction With Pharmacokinetic Assessment in Healthy Subjects.

The goal of this clinical trial is to determine the effect of a mucoadhesive system that releases the vitamin A derivative, fenretinide (FMS), on precancerous surface epithelial (lining tissue inside your mouth) changes. Specifically, does application of the FMS induce specific changes: 1) reduction in the clinical size, 2) reduction in the histologic grade of precancerous changes (determined by microscopic examination), 3) reduce the nuclear LOH events (changes in copy number of key genes to prevent oral cancer).
The first part of this study entails a single FMS application to persons having their wisdom teeth removed. This study is done to confirm how long the FMS needs to remain in place to release the cancer-preventive agent.
Participants will: 1) Have the FMS applied over the impacted wisdom tooth for 15 minutes, 2) FMS is removed, saliva is collected, and blood is drawn from a vein in the arm. 3) Tissue overlying the impacted wisdom tooth is removed and analyzed.
The second, multi-FMS application entails patients who have precancerous oral surface epithelial changes. These patients will have: 1) a piece of the precancerous tissue removed (biopsy) and examined under a microscope to ensure the diagnosis. Blood is drawn from a vein in the arm., 2) One week after the biopsy, return to discuss the results. If the changes are precancerous, this person will be given FMS to apply to the site twice a day. 3) Patients return every 7 to 10 days (for a total of six weeks) for an oral exam and clinical pictures, return the FMS, and obtain new FMS for the upcoming week., 4) At week 3 (midway), blood is drawn from a vein in the arm., 5) After the six weeks of treatment, clinical pictures are obtained, blood is drawn from a vein in the arm and all of the remaining treated tissue is completely removed. The patient is securely contacted and results are discussed. 6) Approximately 6 weeks after the final surgery, patients return for a complete oral examination and clinical pictures are obtained.

开始日期2025-09-01

申办/合作机构

The Ohio State University

[+1]

NCT06528457

/ Completed临床2期

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Examine the Prophylactic and Treatment Effects of a Single Dose Level of Oral Fenretinide in a Dengue Virus Challenge Model

This randomized, placebo controlled single center study examines the extent to which 600 mg/m2/day of orally administered ISLA101 (fenretinide), given prophylactically or therapeutically, may reduce or eliminate signs and symptoms of dengue virus (DENV) infection over 29 days following subcutaneous challenge of healthy subjects with 'Dengue 1 Live Virus Human Challenge' (DENV-1-LVHC). Humoral and cellular immune responses, both innate and adaptive, circulating virus, and changes in clinical laboratory measures will also be examined.

开始日期2024-09-05

申办/合作机构

Island Pharmaceuticals Ltd.

100 项与芬维A胺相关的临床结果

登录后查看更多信息

100 项与芬维A胺相关的转化医学

登录后查看更多信息

100 项与芬维A胺相关的专利（医药）

登录后查看更多信息

1,071

项与芬维A胺相关的文献（医药）

2026-01-22·JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Prognosis and immunotherapeutic implications of molecular classification of cervical cancer based on immunophenoscore-related genes

Article

作者: Lin, Xiurong ; Guo, Aihua ; Feng, Mei ; Wang, Linghua ; Zhong, Peilin

The immunophenoscore (IPS) is an important indicator for evaluating immunotherapy response. This work was designed to establish a prognostic model based on IPS-related genes in cervical cancer. Weighted correlation network analysis (WGCNA) was utilized to identify key modules related to IPS in cervical cancer data from The Cancer Genome Atlas (TCGA). The results show that the yellow module (158 genes) had a high correlation with both IPS_CTLA4_blocker and IPS_CTLA4_and PC1/PDL1/PDL2 blocker. Univariate cox regression analysis and LASSO regression analysis were performed based on 158 genes, and 9 characteristic genes were finally identified to construct the model. According to the differentially expressed genes, cervical cancer samples were divided into high-risk and low-risk groups and cluster 1.2.3. Higher risk scores associated with poorer prognosis. cluster2 and cluster3 were identified as cervical cancer subtypes with significant survival differences. cluster2 had higher immune cell infiltration levels and better prognosis, with greater sensitivity to Cyclopamine, Imatinib, MG-13, Paclitaxel, PHA-665752, Rapamycin, Sorafenib, Sunitinib, and VX-680. In contrast, cluster3 had higher TTN and PIK3CA mutations and greater sensitivity to AZ628, Dasatinib, Doxorubicin, HG-6-64-1, JQ12, Midostaurin, PF-562271, TAE684, and WH-4-023. In conclusion, we developed a feasible risk score model based on IPS-related genes for cervical cancer prognosis and identified potential drugs for different cervical cancer subtypes.

2026-01-01·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Paclitaxel and rose bengal loaded microbubbles for the ultrasound targeted chemo-sonodynamic therapy of pancreatic cancer

Article

作者: Love, Mark ; Kamila, Sukanta ; Stride, Eleanor ; McHale, Anthony P ; Ruan, Jia-Ling ; Logan, Keiran ; McClenaghan, Chloe ; Wright, Jack ; McKaig, Thomas ; Callan, John F ; Nesbitt, Heather ; Taylor, Mark A

Despite significant advances in cancer treatment over the past five decades, survival outcomes for pancreatic cancer have remained largely unchanged. The effectiveness of chemotherapy as a treatment for pancreatic cancer is limited by the dense, protective tumour stroma, which impedes drug delivery. Ultrasound-targeted microbubble destruction (UTMD) has emerged as a promising strategy for enhancing the delivery of chemotherapy agents to solid tumours. In this study, we report the development and evaluation of a novel microbubble (MB) formulation, ST-001, which incorporates paclitaxel chemotherapy and a Rose Bengal sonosensitiser for targeted chemo-sonodynamic therapy of pancreatic cancer. The principle of UTMD using ST-001 was demonstrated in a murine model of pancreatic cancer, where B-mode ultrasound imaging was used to visualize MB accumulation within the tumour and its subsequent clearance following the application of therapeutic ultrasound. Preclinical efficacy studies demonstrated a significant survival advantage in ST-001 treated mice, which survived more than twice as long as those treated with standard Taxol, despite receiving only 14% of the paclitaxel dose. Additionally, a preclinical toxicology study in healthy mice demonstrated an excellent safety profile for ST-001, with no adverse effects observed in key hematological and blood biochemical markers, or in the histology of the spleen, liver, and kidneys.

2025-10-01·FOOD MICROBIOLOGY

Resistance development and transcriptional responses of Salmonella enterica strains to bacteriophage SF1 treatment on Arabidopsis thaliana

Article

作者: Chantapakul, Bowornnan ; Chen, Lin ; Wang, Siyun ; Zhao, Xue

This study explores the prevalence and mechanisms of in vitro and in planta phage resistance in Salmonella enterica, a critical concern for food safety. We examined three Salmonella Typhimurium strains, ST001, ST536, and ST580, that developed phage resistance on Arabidopsis plants. Strains ST001 and ST536 exhibited strong phage resistance and cross-resistance to heat, while ST580 was more susceptible, showing greater population declines and requiring a longer adaptation period. Interestingly, despite gaining phage resistance, all three strains became more sensitive to oxidative and acidic stressors, suggesting potential applications for food industry controls. RNA-seq analysis indicated diverse transcriptional responses to phage exposure: ST580 displayed significant gene expression changes, while ST001 and ST536 increased resistance through enhanced membrane protein synthesis and upregulated ribosome and membrane protein localization genes. ST001 also reduced O-antigen synthesis, blocking the SF1 phage receptor. These transcriptional trends were corroborated by phage attachment assays and membrane protein measurements, highlighting distinct adaptive mechanisms. Unlike ST001 and ST536, ST580's resistance was inadequate to prevent phage adsorption, leading to more reactive transcriptional responses. This research underscores the complexity of phage-host interactions and reveals potential trade-offs, such as increased sensitivity to oxidative and acidic stresses. It offers insights into the dynamics of phage resistance, which could improve phage applications against foodborne pathogens, enhancing the efficacy and sustainability of phage-based safety interventions.

项与芬维A胺相关的新闻（医药）

2026-03-30

·18A反向指标

每周行业深度报告汇总-2026.03.29

报告期间：2026年03月23日 - 2026年03月29日一、上周重磅临床数据发布1. Abcuro Ulviprubart在包涵体肌炎中显示50%疾病进展延缓 ·药物：Ulviprubart ·靶点：肌肉萎缩相关靶点 ·适应症：包涵体肌炎（Inclusion Body Myositis） ·试验阶段：II/III期（MUSCLE研究） ·患者人数：多中心临床试验 ·疗效数据： o疾病进展延缓：50%相对于安慰剂 ·安全性：未报告严重不良事件 ·相关标的：Abcuro Inc. ·来源：BioSpace | 2026年3月 ·原文链接：https://www.biospace.com/press-releases/abcuro-presents-results-from-phase-2-3-muscle-study-of-ulviprubart-in-patients-with-inclusion-body-myositis-at-gcom-20262. SciTech ST-001 nanoFenretinide在皮肤T细胞淋巴瘤中展现临床获益 ·药物：ST-001 nanoFenretinide ·靶点：视黄酸受体 ·适应症：皮肤T细胞淋巴瘤（Cutaneous T-Cell Lymphoma） ·试验阶段：I期（首次人体试验） ·患者人数：早期临床数据 ·疗效数据： o临床获益：确认 o全身暴露：高 o毒性：可控 ·安全性：毒性可管理 ·相关标的：SciTech Development Inc. ·来源：BioSpace | 2026年3月25日 ·原文链接：https://www.biospace.com/press-releases/clinical-data-on-st-001-nanofenretinide-to-be-presented-at-usclc-annual-workshop-20263. AstraZeneca Tozorakimab在慢性肺病中取得III期突破性进展 ·药物：Tozorakimab ·靶点：呼吸道炎症相关靶点 ·适应症：慢性肺病 ·试验阶段：III期 ·患者人数：多中心试验 ·疗效数据： o试验结果：突破性进展 o股价反应：+2.7% ·安全性：未报告重大安全问题 ·相关标的：AstraZeneca（NASDAQ: AZN） ·来源：The Chronicle-Journal | 2026年3月27日 ·原文链接：http://markets.chroniclejournal.com/chroniclejournal/article/marketminute-2026-3-27-astrazeneca-azn-shares-rally-after-breakthrough-chronic-lung-disease-trial-results4. Hope Medicine HMI-115子宫内膜异位症III期试验首例患者给药 ·药物：HMI-115 ·靶点：单克隆抗体 ·适应症：子宫内膜异位症 ·试验阶段：III期 ·患者人数：首例患者已给药 ·疗效数据： o试验状态：首例患者给药，试验正式启动 ·安全性：试验进行中 ·相关标的：Hope Medicine Inc. ·来源：BioSpace | 2026年3月24日 ·原文链接：https://www.biospace.com/press-releases/hope-medicine-announces-first-patient-dosed-in-the-phase-iii-clinical-trial-for-endometriosis5. Novocure TTFields在转移性胰腺癌II期PANOVA-4试验中获阳性结果 ·药物：Tumor Treating Fields（TTFields） ·靶点：肿瘤电场疗法 ·适应症：转移性胰腺癌 ·试验阶段：II期（PANOVA-4） ·患者人数：多中心试验 ·疗效数据： o顶线结果：阳性 ·安全性：未报告新的安全信号 ·相关标的：Novocure（NASDAQ: NVCR） ·来源：BioSpace | 2026年3月 ·原文链接：https://www.biospace.com/press-releases/novocure-announces-positive-topline-results-from-phase-2-panova-4-clinical-trial-of-tumor-treating-fields-ttfields-therapy-for-metastatic-pancreatic-cancer6. ImmunityBio ANKTIVA在BCG初治NMIBC关键性试验中确认统计学效力 ·药物：ANKTIVA ·靶点：免疫激活（IL-15超激动剂） ·适应症：BCG初治非肌层浸润性膀胱癌（NMIBC） ·试验阶段：III期（关键性随机对照试验） ·患者人数：多中心随机对照试验 ·疗效数据： o统计学效力：确认 o临床意义差异检测能力：可检测 ·安全性：进行中 ·相关标的：ImmunityBio ·来源：BioSpace | 2026年3月 ·原文链接：https://www.biospace.com/press-releases/immunitybio-confirms-statistical-power-in-pivotal-randomized-bcg-naive-nmibc-trial-to-detect-clinically-meaningful-differences-between-anktiva-plus-bcg-versus-bcg-alone-supplemental-bla-submission-on-track-for-20267. 28bio CNS-3D脑类器官癫痫预测研究达到主要终点 ·药物：CNS-3D脑类器官平台 ·靶点：神经毒性预测 ·适应症：小分子药物临床癫痫风险预测 ·试验阶段：临床前/平台验证（Endurance研究） ·患者人数：体外模型研究 ·疗效数据： o主要终点：达到 o预测准确性：优于传统动物模型 ·安全性：非临床研究 ·相关标的：28bio ·来源：BioSpace | 2026年3月23日 ·原文链接：https://www.biospace.com/press-releases/28bios-endurance-study-meets-primary-endpoint-showing-cns-3d-brain-organoids-predict-clinical-seizure-liability二、上周重大里程碑进展1. Corcept Therapeutics Lifyorli获FDA加速批准用于铂耐药卵巢癌 ·事件：FDA批准Lifyorli（relacorilant）用于铂耐药卵巢癌、输卵管癌或原发性腹膜癌，较PDUFA日期提前约4个月 ·意义：首个选择性糖皮质激素受体拮抗剂（SGRA）获批肿瘤适应症；标志Corcept从Cushing综合征单一领域向肿瘤学的战略扩展，开辟全新商业化赛道 ·相关标的：Corcept Therapeutics（NASDAQ: CORT） ·来源：The Chronicle-Journal / pharmaphorum | 2026年3月25日 ·原文链接：http://markets.chroniclejournal.com/chroniclejournal/article/finterra-2026-3-26-the-second-act-a-deep-dive-into-corcept-therapeutics-and-the-fda-approval-of-lifyorli2. Novo Nordisk Awiqli获FDA批准为全球首个每周一次基础胰岛素 ·事件：FDA批准Awiqli（insulin icodec-abae）注射液700单位/mL，用于2型糖尿病成人患者辅助饮食和运动控制血糖 ·意义：全球首个且唯一的每周一次长效基础胰岛素，将注射频率从每日降至每周，显著改善患者依从性 ·相关标的：Novo Nordisk ·来源：BioSpace | 2026年3月26日 ·原文链接：https://www.biospace.com/press-releases/fda-approves-novo-nordisks-awiqli-the-first-and-only-once-weekly-basal-insulin-treatment-for-adults-with-type-2-diabetes3. Rocket Pharmaceuticals KRESLADI获FDA加速批准用于儿童LAD-I ·事件：FDA加速批准KRESLADI（marnetegragene autotemcel）用于严重白细胞粘着缺陷I型（LAD-I）儿童患者 ·意义：首个获批的LAD-I基因疗法，为这一危及生命的罕见免疫缺陷病提供根治性治疗选项；为Rocket后续基因疗法产品商业化奠定基础 ·相关标的：Rocket Pharmaceuticals（NASDAQ: RCKT） ·来源：BioSpace / pharmaphorum | 2026年3月 ·原文链接：https://www.biospace.com/press-releases/rocket-pharmaceuticals-announces-fda-approval-of-kresladi-for-pediatric-patients-with-severe-leukocyte-adhesion-deficiency-i-lad-i4. Denali Therapeutics Avlayah获FDA加速批准用于Hunter综合征神经并发症 ·事件：FDA加速批准Avlayah用于Hunter综合征（MPS II）神经学并发症，基于I/II期47例患者数据 ·意义：首个获批治疗Hunter综合征神经学并发症的药物，填补20年以上的治疗空白 ·相关标的：Denali Therapeutics ·来源：BioSpace / pharmaphorum | 2026年3月 ·原文链接：https://pharmaphorum.com/news/fda-clears-denalis-game-changer-hunter-syndrome-drug5. EMA CHMP 3月会议推荐5款新药获批、13款适应症扩展 ·事件：EMA人用药品委员会（CHMP）2026年3月23-26日会议推荐5款新药获条件性上市许可，另有13款药物获适应症扩展推荐 ·意义：欧洲监管端密集放行，多个创新疗法即将进入欧洲市场 ·相关标的：多个欧洲及跨国制药公司 ·来源：European Medicines Agency | 2026年3月26日 ·原文链接：https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-march-20266. EndoCyclic Therapeutics ENDO-205获FDA IND批准 ·事件：FDA批准ENDO-205的IND申请，这是首个非激素精准肽类疗法，用于子宫内膜异位症 ·意义：代表子宫内膜异位症治疗的全新非激素方向，有望规避传统激素疗法的副作用 ·相关标的：EndoCyclic Therapeutics ·来源：BioSpace | 2026年3月23日 ·原文链接：https://www.biospace.com/press-releases/endocyclic-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-endo-205-a-first-in-class-non-hormonal-precision-peptide-therapeutic-for-endometriosis三、上周融资与交易进展汇总1. Merck收购Terns Pharmaceuticals 67亿美元全现金收购 ·交易双方：Merck & Co.（买方）↔ Terns Pharmaceuticals（卖方） ·交易结构： o预付款：67亿美元（全现金） o里程碑：不适用 o总交易价值：67亿美元 ·资产/管线：TERN-701（口服BCR-ABL抑制剂，用于慢性髓性白血病CML），有望挑战Novartis Scemblix的市场地位 ·相关标的：Merck & Co.（NYSE: MRK） ·来源：CNBC / Endpoints News | 2026年3月25日 ·原文链接：https://www.cnbc.com/2026/03/25/merck-buy-terns-pharmaceuticals-mrk-stock-boost-cancer-pipeline.html2. Novartis收购Excellergy 最高20亿美元 ·交易双方：Novartis（买方）↔ Excellergy（卖方，加州生物技术公司） ·交易结构： o总交易价值：最高20亿美元 ·资产/管线：Excellergy创新肿瘤学管线 ·相关标的：Novartis（NOVN.S） ·来源：Reuters | 2026年3月27日 ·原文链接：https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-buy-us-based-biotech-firm-excellergy-up-2-billion-2026-03-27/3. Eli Lilly与Insilico Medicine达成全球AI药物开发合作最高27.5亿美元 ·交易双方：Eli Lilly（买方）↔ Insilico Medicine（卖方） ·交易结构： o全球许可和研发合作：最高27.5亿美元 ·资产/管线：Insilico Medicine生成式AI药物开发平台，聚焦口服小分子疗法研发 ·相关标的：Eli Lilly（NYSE: LLY）、Insilico Medicine（3696.HK） ·来源：Reuters / Fierce Biotech | 2026年3月29日 ·原文链接：https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-sign-2-billion-deal-ai-drug-development-with-hong-kongs-insilico-2026-03-29/4. Otsuka收购Transcend Therapeutics 12.25亿美元 ·交易双方：Otsuka Pharmaceutical（买方）↔ Transcend Therapeutics（卖方） ·交易结构： o预付款：7亿美元 o总交易价值：12.25亿美元 ·资产/管线：MDMA类似物，用于精神类疾病治疗 ·相关标的：Otsuka Pharmaceutical ·来源：Fierce Biotech | 2026年3月 ·原文链接：https://www.fiercebiotech.com/biotech/otsuka-picks-transcend-1225b-acquisition-highlighting-mdma-analog5. Pinnacle Medicines完成8900万美元B轮融资（超额认购） ·交易双方：LAV、Foresite Capital等投资方 ↔ Pinnacle Medicines ·交易结构： oB轮融资：8900万美元（超额认购） ·资产/管线：口服肽类疗法管线，用于免疫学和心脏代谢疾病，推进进入临床试验 ·相关标的：Pinnacle Medicines（上海/宾夕法尼亚双总部） ·来源：BioSpace | 2026年3月26日 ·原文链接：https://www.biospace.com/press-releases/pinnacle-medicines-a-pioneer-of-oral-peptide-therapeutics-announces-oversubscribed-89-million-series-b-financing-to-advance-pipeline-into-clinical-trials6. Gilgamesh Pharma完成6000万美元A轮融资（超额认购） ·交易双方：机构投资方↔ Gilgamesh Pharma ·交易结构： oA轮融资：6000万美元（超额认购） ·资产/管线：下一代神经精神类疾病疗法（精神和神经障碍） ·相关标的：Gilgamesh Pharma ·来源：BioSpace | 2026年3月24日 ·原文链接：https://www.biospace.com/press-releases/gilgamesh-pharma-closes-oversubscribed-60-million-series-a-to-develop-next-generation-neuropsychiatric-therapies7. Earendil Labs获7.87亿美元融资（Sanofi、Pfizer支持） ·交易双方：Sanofi、Pfizer等战略投资方 ↔ Earendil Labs ·交易结构： o融资总额：7.87亿美元 ·资产/管线：AI驱动生物制剂设计平台，已产生40余个项目，包括与Sanofi的抗炎资产合作 ·相关标的：Earendil Labs ·来源：BioSpace | 2026年3月 ·原文链接：https://www.biospace.com/business/backed-by-sanofi-pfizer-earendil-bags-787m-for-ai-driven-biologics-design8. ImmuneBridge获770万美元融资，开放细胞疗法制造平台 ·交易双方：机构投资方↔ ImmuneBridge ·交易结构： o融资金额：770万美元 ·资产/管线：细胞疗法筛选和制造平台，向外部生物技术合作伙伴开放共同开发 ·相关标的：ImmuneBridge ·来源：HIT Consultant | 2026年3月24日 ·原文链接：https://hitconsultant.net/2026/03/24/immunebridge-7-7m-funding-cell-therapy-manufacturing-platform-scale/ 备注：虾哥今天抽风，忘了优先使用中文名。临床数据部分 Hope Medicine Inc. → 和其瑞医药（Hope Medicine Inc.，上海）融资与交易部分 Eli Lilly ↔ Insilico Medicine → 礼来 ↔ 英矽智能（Insilico Medicine，3696.HK） Pinnacle Medicines → 鼎泰医药（Pinnacle Medicines，上海/宾夕法尼亚） Sanofi、Pfizer → 赛诺菲、辉瑞

2026-03-25

·PRNewswire

Clinical Data on ST-001 nanoFenretinide™ to be presented at USCLC Annual Workshop 2026

Results Highlight Early Clinical Benefit, High Systemic Exposure, and Manageable Toxicity in Cutaneous T-Cell Lymphoma Patients DETROIT, March 25, 2026 /PRNewswire/ -- SciTech Development Inc., a clinical-stage oncology company advancing ST-001 nanoFenretinide™, today announced that early-stage clinical data from SciTech's ongoing Phase 1a trial will be presented at the USCLC Annual Workshop 2026 in Denver, Colorado on March 26, 2026. Principal investigator, Auris Huen, MD, PharmD, associate professor of Dermatology at The University of Texas MD Anderson Cancer Center, will present "Clinical Benefit, High Systemic Exposure, and Manageable Toxicity in a First-in-Human Trial of ST-001 nanoFenretinide™ in Previously Treated Cutaneous T-Cell Lymphoma" which will highlight emerging data from SciTech's clinical trial evaluating ST-001 in patients with Cutaneous T-Cell Lymphoma (CTCL), a subtype of T-cell non-Hodkin lymphoma. The presentation will feature early clinical findings demonstrating meaningful anti-tumor activity, including complete and partial responses, alongside a favorable safety and tolerability profile. The data also underscores the ability of ST-001's proprietary nanoparticle delivery platform to achieve enhanced systemic exposure—addressing a longstanding bioavailability limitation of fenretinide and supporting its therapeutic potential. SciTech's Phase 1a trial is fully enrolled and nearing completion, and data support the advancement of ST-001 into the next phase of clinical development. The USCLC Annual Workshop convenes leaders in cutaneous lymphoma to discuss advances in diagnostics, therapeutics, and patient care. The 2026 theme, "Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics, and Future Directions," highlights the accelerating pace of innovation in the field. "We are honored to have Dr. Huen present these important findings," said Earle Holsapple, CEO of SciTech Development. "Her medical expertise and leadership in CTCL, combined with the encouraging early data, continue to strengthen SciTech's confidence in ST-001 as a potentially impactful therapy for patients with limited treatment options." In addition to its CTCL program, SciTech recently received FDA clearance of its Investigational New Drug (IND) application to initiate a Small Cell Lung Cancer (SCLC) trial, further expanding the potential of its platform across multiple oncology indications. About SciTech Development, Inc. SciTech Development, Inc. is a clinical-stage pharmaceutical company focused on advancing innovative oncology therapies. Its lead drug, ST-001 nanoFenretinide™, leverages a proprietary nanoparticle delivery technology designed to enhance drug bioavailability and therapeutic effect. The Company is advancing ST-001 in T-cell non-Hodgkin lymphoma (T-cell NHL), with a planned clinical trial in Small Cell Lung Cancer, with ongoing evaluation of additional oncology indications to expand its therapeutic reach. For more information, please visit: Forward-Looking Statements This press release contains forward-looking statements regarding future clinical development, clinical data, and potential commercialization. Actual results may differ materially due to various risks and uncertainties, including clinical development risks, regulatory review, and market conditions. Media Contact: David Schaffer | +1-727-278-8188 | [email protected] SOURCE SciTech Development, Inc. 21% more press release views with Request a Demo

临床1期临床申请细胞疗法

2026-01-30

·PRNewswire

Solace Nutrition Announces Clinical and Scientific Updates for Encala®, the Original Structured-Lipid Medical Food for Fat Malabsorption

NORTH STONINGTON, Conn., Jan. 30, 2026 /PRNewswire/ -- Solace Nutrition, a trusted leader in tailored clinical nutrition and medical foods, today announced significant clinical, scientific, and commercial updates for Encala®, its proprietary plant-based structured-lipid medical food designed to address fat malabsorption, fatty acid and choline deficiencies, poor growth in children, and unintentional weight loss in adults. Since the February 2025 relaunch of Encala, sales supporting both adult and pediatric nutritional care have exceeded projections. Many health care providers recognized the Encala brand from its earlier availability through Envara Health, Inc., recalling its predictable benefits for weight gain and gastrointestinal symptom improvement in patients with malabsorption. "In the past year, Solace Nutrition established in-house manufacturing, comprehensive patient support, insurance coverage assistance, and dedicated health care provider services with a full-time team," said Thomas Clough, CEO of Solace Nutrition. "We are now well positioned to meet increasing patient demand across a wide range of malabsorption conditions." Encala is currently being utilized by patients with pancreatic and intestinal diseases, short bowel syndrome, and other complex gastrointestinal conditions. Solace Nutrition plans to expand Encala availability internationally, with a Canadian launch anticipated in the third quarter of 2026 and expansion into South America by the fourth quarter. Targeted patient populations include those living with cystic fibrosis, short bowel syndrome, rare pancreatic diseases, and patients requiring ICU enteral nutrition support. Scientific Foundation and Clinical Legacy Encala was developed following highly positive outcomes from a large NIH-funded randomized clinical trial led by Virginia Stallings, MD, an internationally recognized pediatric nutrition scientist. The trial evaluated 110 children and adolescents living with cystic fibrosis and demonstrated clinically meaningful improvements in growth and nutritional status. The research was designed and conducted by David Yesair, PhD, inventor of the structured lipid compound; Walter Shaw, PhD, lipid biochemist responsible for manufacturing the original research-only formulation (Lym-X-Sorb®); and Dr. Stallings, who served as principal investigator. The research team published eight peer-reviewed papers and presented results nationally and internationally. Including NIH grant funding and support from Envara Health, Inc. (founded by Dr. Stallings), more than $17 million has been invested in the development of today's Encala. A major milestone in this effort was the establishment of a CMS reimbursement code, enabling broader access and insurance coverage for eligible patients. To translate decades of research into sustainable, patient-centered care, Structured Lipid Nutrition, LLC was formed to preserve the Encala technology and brand. In 2024, Structured Lipid Nutrition partnered with Solace Nutrition to provide high-quality manufacturing, distribution, and seamless support for patients and health care providers. Encala Research Updates Pancreatic Cancer A Department of Defense–funded clinical nutrition study launched in September 2025 at the University of Pennsylvania Abramson Cancer Center and Children's Hospital of Philadelphia. The study enrolls individuals with pancreatic ductal adenocarcinoma (PDAC) and neuroendocrine pancreatic tumors (NET) to evaluate gastrointestinal symptoms and quality of life during Encala nutritional intervention. Faculty investigators include Drs. Stallings, Brownell, and Teitelbaum. Cerebral Palsy A study evaluating the nutritional impact of Encala in children and adults with moderate to severe cerebral palsy requiring enteral tube feeding is under review for Institutional Review Board approval. Enrollment is expected to begin in March 2026. Oral Drug Delivery Encala's structured-lipid technology has demonstrated the ability to enhance oral absorption of lipid-soluble medications, including fenretinide. A novel drug delivery and nutrition application is in development, supported by animal and healthy human dosing studies with favorable outcomes. Research Software Inclusion Encala has been incorporated into the Nutrition Data System for Research (NDSR®), the gold-standard dietary analysis software used in clinical trials and epidemiological research across the United States and Canada. Encala intake will be analyzed using NDSR in the pancreatic cancer study, and its full nutrient composition is now accessible to health care providers and researchers. Veterinary Research An eight-week nutrition rehabilitation study in malnourished dogs demonstrated positive safety, feasibility, weight gain, and lean body mass outcomes. Findings were presented at regional and national veterinary meetings, with an abstract expected for presentation at the International Veterinary Nutrition Conference in June 2026. A separate palatability study in healthy cats confirmed strong acceptance of Encala when incorporated into both dry and moist foods, with no adverse gastrointestinal effects observed. About Structured Lipid Nutrition Structured Lipid Nutrition (SLN) was founded by Virginia Stallings, MD, to develop and commercialize evidence-based nutritional solutions addressing unmet medical needs across human and veterinary health. SLN preserved the Encala® medical food technology and clinically recognized brand and partnered with Solace Nutrition to support large-scale manufacturing, distribution, and clinical support. Together, SLN and Solace Nutrition continue to advance clinical research and product development focused on improving growth, weight, lean body mass, and key biomarkers including fatty acids and choline. The Encala-Inside® technology platform supports innovation across human nutrition, veterinary nutrition, and oral drug delivery. About Solace Nutrition Solace Nutrition is a medical nutrition company specializing in the development and manufacturing of science-backed medical foods for individuals with complex metabolic and chronic conditions. With more than 20 years of clinical nutrition expertise, the company is a trusted provider of safe, reliable, and effective nutritional solutions. Solace Nutrition is committed to advancing patient care by improving access to specialized nutrition that supports better health and quality of life. For media inquiries, interviews, or product information, please contact: Kate Murtaugh, Marketing Director, Solace Nutrition +1 (401) 793-1758 [email protected] SOURCE Solace Nutrition 21% more press release views with Request a Demo

临床结果

100 项与芬维A胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04162	芬维A胺	-	DB05076

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床3期	加拿大	Laurent Pharmaceuticals, Inc.	2023-11-15
新型冠状病毒感染	临床3期	美国	Laurent Pharmaceuticals, Inc.	2020-08-18
BRCA突变阳性乳腺癌	临床3期	意大利	Istituto Europeo di Oncologia Srl	2009-12-01
HR阳性乳腺癌	临床3期	美国	Eastern Cooperative Oncology Group	1995-10-01
乳腺癌	临床3期	-	Laurent Pharmaceuticals, Inc.	-
乳腺癌	临床3期	-	Johnson & Johnson	-
登革热	临床2期	美国	Island Pharmaceuticals Ltd.	2024-09-05
囊性纤维化	临床2期	美国	Laurent Pharmaceuticals, Inc.	2018-11-05
囊性纤维化	临床2期	澳大利亚	Laurent Pharmaceuticals, Inc.	2018-11-05
囊性纤维化	临床2期	加拿大	Laurent Pharmaceuticals, Inc.	2018-11-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05999435 (ESSOR, CTgov)	临床2/3期	新冠肺炎后遗症	272	LAU-7b (LAU-7b for 3 Cycles (Arm 1, AAA))	壓齋願繭鏇觸顧窪壓範(構繭壓鬱顧顧選顧積夢) = 顧構壓鑰簾選鑰餘鹹廠齋願築齋艱構鑰鏇構願 (簾齋選鹽鬱遞衊蓋襯鹹, 9.267) 更多	-	2026-01-06
				Placebo+LAU-7b (LAU-7b for 1 Cycle, Then Placebo (Arm 2, APP))	壓齋願繭鏇觸顧窪壓範(構繭壓鬱顧顧選顧積夢) = 醖醖網鏇顧蓋獵構獵壓齋願築齋艱構鑰鏇構願 (簾齋選鹽鬱遞衊蓋襯鹹, 7.941) 更多
NCT04417257 (RESOLUTION, CTgov)	临床2/3期	新型冠状病毒感染	351	LAU-7b (LAU-7b Phase 2)	遞獵構顧繭範顧醖鏇壓 = 鏇繭鹹觸簾選顧壓繭築繭壓範範憲獵範壓鏇鏇 (範鹽襯糧憲襯膚觸網範, 網積範糧夢窪膚構網鹽 ~ 獵獵廠獵網糧醖築積遞) 更多	-	2025-11-13
				Placebo (Placebo Phase 2)	遞獵構顧繭範顧醖鏇壓 = 築鹹願構鏇憲餘願築鬱繭壓範範憲獵範壓鏇鏇 (範鹽襯糧憲襯膚觸網範, 齋獵鏇蓋獵選鏇鹽夢衊 ~ 顧夢願選齋艱齋網糧選) 更多
PRNewswire 人工标引	临床1期	肿瘤	-	Fenretinide	膚鹽醖憲築衊鏇選獵鑰(築願夢膚積餘衊獵觸蓋) = 鹽願鬱構鬱鹹顧鏇餘糧淵鹽網衊糧鹹獵齋糧餘 (廠衊築艱築獵膚積鹽範 )	积极	2025-09-24
NCT04234048 (PRNewswire) 人工标引	临床1期	T细胞淋巴瘤	-	ST-001	繭鏇製遞襯築築憲願窪(窪夢齋築鏇襯獵廠鹽鑰) = earlier-than-anticipated stable disease and partial responses - one initial and one confirmed. 範積觸願鑰築構繭製糧 (顧積襯餘鬱艱願鹽遞衊 ) 更多	积极	2024-12-03
NCT03265288 (APPLAUD, CTgov)	临床2期	囊性纤维化	166	LAU-7b (LAU-7b)	簾膚憲衊壓觸網鏇淵鏇(衊繭鹹鹹獵選製蓋選糧) = 衊選顧獵齋夢壓襯鹽廠範齋製顧繭蓋積蓋範壓 (壓鹽鹽鹽壓壓淵糧鬱衊, 築膚憲糧鑰餘憲鹽廠繭 ~ 顧範齋衊鬱壓鹹憲鏇鑰) 更多	-	2024-10-09
				Placebo oral capsule (Placebo)	簾膚憲衊壓觸網鏇淵鏇(衊繭鹹鹹獵選製蓋選糧) = 鹽廠膚窪獵襯淵鹹淵壓範齋製顧繭蓋積蓋範壓 (壓鹽鹽鹽壓壓淵糧鬱衊, 蓋鬱顧鬱淵繭廠築窪願 ~ 窪襯窪齋淵糧鏇顧築鹹) 更多
NCT01553071 (Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies, Pubmed \| Cancer Chemother Pharmacol)	临床1期	肿瘤	16	Fenretinide	範繭夢構壓艱蓋廠齋醖(範範膚顧繭膚窪鏇範廠) = 選窪網觸齋獵壓顧範醖憲構範襯衊糧鹽蓋窪觸 (鑰憲築襯簾蓋窪築願醖 )	不佳	2023-08-01
NCT03265288 (APPLAUD, Biospace) 人工标引	临床2期	囊性纤维化	166	LAU-7b	鹽獵獵壓襯選積構餘鏇(簾鏇鏇鬱網糧蓋窪觸簾): difference = 1.23, P-Value = 0.0486	积极	2022-11-03
				Placebo
NCT00546455 (CTgov)	临床2期	胰岛素抵抗 \| 肝炎 \| 代谢功能障碍相关的脂肪肝病 ... 更多	21	Fenretinide (A- Fenretinide)	衊鬱築網餘繭襯廠壓艱(鏇願鑰廠鬱選鏇鑰齋壓) = 憲廠獵鬱窪夢蓋鹽構築製齋壓餘繭蓋獵艱醖蓋 (窪願構壓簾鹹繭繭網簾, 夢繭鏇製構廠餘築網淵 ~ 廠憲製廠築觸繭襯鏇網) 更多	-	2021-02-10
				placebo (B-Placebo)	衊鬱築網餘繭襯廠壓艱(鏇願鑰廠鬱選鏇鑰齋壓) = 積積獵艱構糧獵製壓餘製齋壓餘繭蓋獵艱醖蓋 (窪願構壓簾鹹繭繭網簾, 製艱糧鏇齋鬱餘壓衊鹽 ~ 製繭鏇鬱廠衊網壓襯廠) 更多
NCT00104923 (Pubmed \| Clin Cancer Res) 人工标引	临床1期	血液肿瘤	29	Fenretinide	鹽艱願廠醖鏇顧範膚糧(簾鑰醖觸齋觸範築獵構) = 築範鹽願糧網襯獵艱構獵鏇窪襯壓壓顧醖製製 (壓願艱鹹觸鑰選鹽蓋遞 )	积极	2017-08-15
				Fenretinide (patients with response-evaluable peripheral T-cell lymphomas)	糧積製夢憲夢襯願遞觸(壓積顧願鬱獵築襯選鹹) = 選選遞繭夢網顧淵構構艱繭衊積網鹹憲鹽夢憲 (齋夢鹹齋窪齋壓鑰夢鬱 ) 更多
NCT00288067 (Pubmed \| Int J Radiat Oncol Biol Phys) 人工标引	临床1/2期	套细胞淋巴瘤 \| B细胞淋巴瘤	32	fenretinide	艱構繭網遞膚醖膚製壓(廠範繭繭網夢簾壓衊夢) = No dose-limiting toxicities were observed. 鏇簾糧壓積襯窪鹽衊選 (廠蓋選遞壓襯齋築醖餘 ) 更多	积极	2017-02-01
				fenretinide+rituximab